{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:24:36Z","timestamp":1788355476467,"version":"build-2803163510"},"reference-count":155,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015763","name":"Szegedi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020275","name":"Vilnius University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019624","name":"Fakultn\u00ed nemocnice Hradec Kr\u00e1lov\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008909","name":"Universitatea de Medicin\u0103 \u015fi Farmacie din T\u00eergu Mure\u0219","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jaip.2025.11.023","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:21:14Z","timestamp":1764202874000},"page":"76-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted Treatment in Asthma\u2014Opportunities and Challenges"],"prefix":"10.1016","volume":"14","author":[{"given":"Ioana","family":"Agache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-8638","authenticated-orcid":false,"given":"Magdalena","family":"Zemelka-Wiacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Gawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve N.","family":"Georas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Jahnz-R\u00f3\u017cyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kupczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Moniuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"M\u04e7sges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Sanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali \u04e6nder","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Jutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Balkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Balner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maris","family":"Bukovskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dojan","family":"Dokic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Jese\u0148\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotryna","family":"Linauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Malinauskien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Nov\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Novosad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Panaitescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Pevec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u016brat\u0117","family":"Staik\u016bnien\u0117-Kozonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Samar\u017eija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanaki","family":"Thalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vogelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Winders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.11.023_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1398-9995.2006.01254.x","article-title":"Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma","volume":"62","author":"Sullivan","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/JAA.S401445","article-title":"Symptom burden, health status, and productivity in patients with uncontrolled and controlled severe asthma in NOVELTY","volume":"16","author":"Ding","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib3","doi-asserted-by":"crossref","first-page":"00709","DOI":"10.1183\/23120541.00709-2024","article-title":"Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics","volume":"11","author":"Liu","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.11.023_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-2600(24)00250-9","article-title":"Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and UBIOPRED: results from two major longitudinal asthma cohorts","volume":"13","author":"Zein","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib6","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/all.15054","article-title":"Advances and highlights in asthma in 2021","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib7","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.11.023_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib11","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jaip.2021.01.033","article-title":"Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms score","volume":"9","author":"P\u00e9rez de Llano","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and metaanalysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1164\/rccm.202408-1544OC","article-title":"Clinical and biological features of a thickened basement membrane zone in asthma","volume":"211","author":"Leung","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2017.08.012","article-title":"Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy","volume":"48","author":"van de Veen","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/all.12966","article-title":"High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers","volume":"72","author":"Boonpiyathad","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/ppul.24881","article-title":"The course of asthma: a population-based 10-year study examining asthma remission in children diagnosed with asthma in preschool","volume":"55","author":"Oluwole","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2025.11.023_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2019.09.030","article-title":"Severe asthma during childhood and adolescence: a longitudinal study","volume":"145","author":"Ross","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1164\/rccm.200712-1818OC","article-title":"Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma","volume":"178","author":"Turato","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1398-9995.2009.02057.x","article-title":"Neutrophilic airway inflammation is a main feature of induced sputum in nonatopic asthmatic children","volume":"64","author":"Drews","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1526-0542(02)00188-4","article-title":"What have we learned from the Tucson Children's Respiratory Study?","volume":"3","author":"Martinez","year":"2002","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jaip.2025.11.023_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/all.15566","article-title":"Biomarkers of asthma relapse and lung function decline in adults with spontaneous asthma remission: a population-based cohort study","volume":"78","author":"Tan","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib23","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/cea.13181","article-title":"Novel genes and insights in complete asthma remission: a genome-wide association study on clinical and complete asthma remission","volume":"48","author":"Vonk","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib24","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M Study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and ontreatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib26","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib27","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1164\/rccm.202308-1413LE","article-title":"Benralizumab normalizes sputum eosinophilia in severe asthma uncontrolled by anti-IL-5 antibodies: a single-blind, placebocontrolled clinical trial","volume":"208","author":"Mukherjee","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/all.16178","article-title":"Real-world biologics response and super-response in the International Severe Asthma Registry cohort","volume":"79","author":"Denton","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1361891","article-title":"Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma","volume":"15","author":"Porsbjerg","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1164\/rccm.202412-2438OC","article-title":"Clinical remission by a comprehensive severe asthma management strategy guided by airway inflammometry and bioimaging","volume":"211","author":"Nolasco","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01497-2024","article-title":"Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma","volume":"65","author":"Soendergaard","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00782-2024","article-title":"Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma","volume":"65","author":"Hamada","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02023-2024","article-title":"Trajectories of responses to mepolizumab in severe asthma","volume":"65","author":"Nolasco","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(18)30529-0","article-title":"Lung function trajectories in health and disease","volume":"7","author":"Agusti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib37","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0140-6736(24)00016-3","article-title":"Lung-function trajectories: relevance and implementation in clinical practice","volume":"403","author":"Mel\u00e9n","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.11.023_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/17476348.2024.2390987","article-title":"Imagining the severe asthma decision trees of the future","volume":"18","author":"Bourdin","year":"2024","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib39","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.rmed.2010.03.030","article-title":"Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV(1)","volume":"104","author":"Broekema","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1164\/rccm.201003-0494OC","article-title":"Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma","volume":"183","author":"Broekema","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing longterm mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00404-2024","article-title":"Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)","volume":"64","author":"Soendergaard","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib44","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01168-2024","article-title":"Stepping down biologics in asthma: is it time to challenge the status quo?","volume":"64","author":"Khurana","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib45","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1056\/NEJMoa051378","article-title":"Long-term inhaled corticosteroids in preschool children at high risk for asthma","volume":"354","author":"Guilbert","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib46","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaci.2015.04.047","article-title":"International consensus on allergy immunotherapy","volume":"136","author":"Jutel","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib47","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying antiasthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.11.023_bib48","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaip.2025.05.003","article-title":"Combination of allergen-specific immunotherapy with biologics in severe asthma: counterintuitive or rational?","volume":"13","author":"Larenas-Linnemann","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/all.13749","article-title":"EAACI Guidelines on Allergen Immunotherapy: house dust mite-driven allergic asthma","volume":"74","author":"Agache","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaip.2023.11.031","article-title":"Allergen immunotherapy for asthma","volume":"12","author":"Kappen","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/all.16052","article-title":"House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study","volume":"79","author":"Jutel","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib52","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/all.13598","article-title":"Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma","volume":"74","author":"Wahn","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/all.13213","article-title":"Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis","volume":"73","author":"Zielen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib54","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/all.15295","article-title":"Allergen immunotherapy for asthma prevention: a systematic review and meta-analysis of randomized and nonrandomized controlled studies","volume":"77","author":"Farraia","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib55","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2025.11.023_bib56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2014.03.019","article-title":"Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Mosbech","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib57","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jaci.2010.06.002","article-title":"Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial","volume":"126","author":"Zielen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib58","article-title":"Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study","volume":"13","author":"Fritzsching","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jaip.2025.11.023_bib59","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00446-2022","article-title":"Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study","volume":"60","author":"Woehlk","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib60","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/all.13208","article-title":"Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis","volume":"72","author":"Dhami","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib62","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202209-1708OC","article-title":"Allergen immunotherapy enhances airway epithelial antiviral immunity in patients with allergic asthma (VITAL Study): a double-blind randomized controlled trial","volume":"207","author":"Woehlk","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib63","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.jaip.2019.06.003","article-title":"Effect of sublingual immunotherapy on airway inflammation and airway wall thickness in allergic asthma","volume":"7","author":"Hoshino","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pulmoe.2019.01.007","article-title":"Immunotherapy in allergic asthma\u20145 year analysis: is it a curative approach?","volume":"25","author":"Coutinho Costa","year":"2019","journal-title":"Pulmonology"},{"key":"10.1016\/j.jaip.2025.11.023_bib65","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.11.023_bib69","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1164\/rccm.202304-0642ST","article-title":"Questions in mild asthma: an official American Thoracic Society research statement","volume":"207","author":"Mohan","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/j.1398-9995.2007.01394.x","article-title":"Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations","volume":"62","author":"Dusser","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib71","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1164\/rccm.202010-3763OC","article-title":"Factors associated with persistence of severe asthma from late adolescence to early adulthood","volume":"204","author":"Izadi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib72","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.rmed.2008.03.020","article-title":"Asthma mortality among Swedish children and young adults, a 10-year study","volume":"102","author":"Bergstr\u00f6m","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib73","doi-asserted-by":"crossref","first-page":"00359","DOI":"10.1183\/23120541.00359-2019","article-title":"The burden of exacerbations in mild asthma: a systematic review","volume":"6","author":"FitzGerald","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.11.023_bib74","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/all.15889","article-title":"Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib75","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently noneosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib76","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","article-title":"Inhaled combined budesonide-formoterol as needed in mild asthma","volume":"378","author":"O'Byrne","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib77","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","article-title":"As-needed budesonide-formoterol versus maintenance budesonide in mild asthma","volume":"378","author":"Bateman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib78","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","article-title":"Controlled trial of budesonide-formoterol as needed for mild asthma","volume":"380","author":"Beasley","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40264-020-01041-z","article-title":"Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies","volume":"44","author":"FitzGerald","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2025.11.023_bib80","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00047-2023","article-title":"European Respiratory Society short guidelines for the use of as-needed ICS\/formoterol in mild asthma","volume":"62","author":"Papi","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib81","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02073-2019","article-title":"Patient preferences for symptomdriven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial","volume":"55","author":"Baggott","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa2504544","article-title":"As-needed albuterol-budesonide in mild asthma","volume":"393","author":"LaForce","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib83","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.rmed.2009.02.015","article-title":"Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma","volume":"103","author":"Boulet","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib84","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaci.2009.10.037","article-title":"Predictors of remitting, periodic, and persistent childhood asthma","volume":"125","author":"Covar","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib85","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa070013","article-title":"Randomized comparison of strategies for reducing treatment in mild persistent asthma","volume":"356","author":"American Lung Association Asthma Clinical Research Centers","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib86","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4187\/respcare.03200","article-title":"Asthma and adherence to inhaled corticosteroids: current status and future perspectives","volume":"60","author":"B\u00e5rnes","year":"2015","journal-title":"Respir Care"},{"key":"10.1016\/j.jaip.2025.11.023_bib87","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jaci.2025.03.025","article-title":"Personalised therapeutic approaches for asthma","volume":"156","author":"Agache","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib88","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.023_bib89","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib90","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S2213-2600(21)00536-1","article-title":"The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study","volume":"10","author":"Kraft","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib91","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1016\/j.jaip.2025.07.002","article-title":"Small airway dysfunction is an independent exacerbation risk biomarker in the mild, well-controlled patient with asthma: a frequently unrecognized high-risk phenotype","volume":"13","author":"Galant","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.023_bib93","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","article-title":"Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative","volume":"5","author":"Blakey","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/1178630218757445","article-title":"Insights into the environmental health burden of childhood asthma","volume":"12","author":"Kelley","year":"2018","journal-title":"Environ Health Insights"},{"key":"10.1016\/j.jaip.2025.11.023_bib95","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/all.16151","article-title":"The impact of exposure to tobacco smoke and e-cigarettes on asthma-related outcomes: systematic review informing the EAACI guidelines on environmental science for allergic diseases and asthma","volume":"79","author":"Agache","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib96","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/thorax.57.3.226","article-title":"Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma","volume":"57","author":"Chalmers","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.023_bib97","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/all.16502","article-title":"EAACI Guidelines on Environmental Science for Allergy and Asthma\u2013recommendations on the impact of indoor air pollutants on the risk of new-onset asthma and on asthma-related outcomes","volume":"80","author":"Agache","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib98","article-title":"EAACI guidelines on environmental science for allergy and asthma: the impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures","volume":"79","author":"Agache","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaip.2024.12.025","article-title":"An overview of climate changes and its effects on health: from mechanisms to one health","volume":"13","author":"Agache","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib100","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/all.15755","article-title":"The One Health approach for allergic diseases and asthma","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib101","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/all.15667","article-title":"EAACI guidelines on environmental science in allergic diseases and asthma\u2014leveraging artificial intelligence and machine learning to develop a causality model in exposomics","volume":"78","author":"Shamji","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib102","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/02770903.2021.2018701","article-title":"Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US CHRONICLE study","volume":"59","author":"Lugogo","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.11.023_bib103","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/2012.jama.10893","article-title":"Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial","volume":"308","author":"Calhoun","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2025.11.023_bib104","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(11)60971-9","article-title":"Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial","volume":"378","author":"Powell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.11.023_bib105","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jaci.2018.02.039","article-title":"Managing Asthma in Pregnancy (MAP) trial: FENO levels and childhood asthma","volume":"142","author":"Morten","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib106","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02150-2019","article-title":"Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis","volume":"55","author":"Wang","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib107","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaip.2023.12.010","article-title":"Association of sputum eosinophilia with easily measured type-2 inflammatory biomarkers in untreated mild persistent asthma","volume":"12","author":"Covar","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib108","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2008.11.016","article-title":"Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma","volume":"123","author":"Knuffman","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib109","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00298-2022","article-title":"Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes","volume":"60","author":"Murphy","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(20)30053-9","article-title":"Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial","volume":"8","author":"Pavord","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib111","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2022.06.028","article-title":"Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways","volume":"151","author":"Agache","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib112","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/all.16060","article-title":"Transcriptomic evaluation of skin tape-strips in children with allergic asthma uncovers epidermal barrier dysfunction and asthma-associated biomarkers abnormalities","volume":"79","author":"Del Duca","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib113","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib114","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines\u2013Recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib115","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jaci.2022.10.007","article-title":"Immunotherapy: state-of-the-art review of therapies and theratypes","volume":"150","author":"Agache","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib116","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/all.15945","article-title":"Hot topics in allergen immunotherapy, 2023: current status and future perspective","volume":"79","author":"Zemelka-Wiacek","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"Horne","year":"1999","journal-title":"Psychol Health"},{"key":"10.1016\/j.jaip.2025.11.023_bib118","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaip.2025.11.023_bib119","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101066","article-title":"Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR)","volume":"18","author":"Schleich","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.11.023_bib121","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.023_bib122","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(15)00419-1","article-title":"Blood or sputum eosinophils to guide asthma therapy?","volume":"3","author":"Mukherjee","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib123","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.023_bib124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12931-023-02437-y","article-title":"Economic impact of a more extensive use of FENO testing on the Italian population with asthma","volume":"24","author":"Rognoni","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2025.11.023_bib126","first-page":"1","article-title":"Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment","volume":"24","year":"2024","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.jaip.2025.11.023_bib127","doi-asserted-by":"crossref","first-page":"89","DOI":"10.18176\/jiaci.0103","article-title":"Cost-effectiveness and budget impact of routine use of fractional exhaled nitric oxide monitoring for the management of adult asthma patients in Spain","volume":"27","author":"Sabatelli","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib128","first-page":"42","article-title":"Cost-effectiveness analysis of monitoring fractional exhaled nitric oxide (FeNO) in the management of asthma","volume":"27","author":"Brooks","year":"2018","journal-title":"Manag Care"},{"key":"10.1016\/j.jaip.2025.11.023_bib129","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2500\/aap.2018.39.4165","article-title":"Cost impact of monitoring exhaled nitric oxide in asthma management","volume":"39","author":"Arnold","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.11.023_bib130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41533-025-00418-w","article-title":"Qualitative insights into planning implementation of FeNO-guided asthma management in primary care","volume":"35","author":"Lewis","year":"2025","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib131","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaip.2022.11.046","article-title":"Clinical potential of eosinophil-derived neurotoxin in asthma management","volume":"11","author":"Malinovschi","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.023_bib132","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/all.16309","article-title":"Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma","volume":"79","author":"Rhee","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib133","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1398-9995.2011.02723.x","article-title":"Alveolar mast cells shift to an Fc\u03b5RI-expressing phenotype in mild atopic asthma: a novel feature in allergic asthma pathology","volume":"66","author":"Andersson","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib134","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.iac.2016.03.004","article-title":"Biomarkers in severe asthma","volume":"36","author":"Wan","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2025.11.023_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ACI.0000000000000412","article-title":"Collection of nasal secretions and tears and their use in allergology","volume":"18","author":"Castelli","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib136","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/all.12817","article-title":"Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia","volume":"71","author":"Rank","year":"2016","journal-title":"Allergy"},{"issue":"Suppl 67","key":"10.1016\/j.jaip.2025.11.023_bib137","article-title":"Assessment of eosinophilic airway inflammation using formalin-fixed, paraffin-embedded sputum plugs","volume":"62","author":"Patel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib138","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib139","first-page":"00604","article-title":"A novel method to assess airway eosinophilia utilizing sputum plugs","volume":"11","author":"Patel","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.11.023_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26949-7","article-title":"A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer","volume":"12","author":"Ali","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2025.11.023_bib141","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaci.2024.03.023","article-title":"Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma","volume":"154","author":"Tang","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib142","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10238-021-00750-8","article-title":"Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma","volume":"22","author":"Varricchi","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib143","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186889","article-title":"Cellular and molecular features of asthma mucus plugs provide clues about their formation and persistence","volume":"135","author":"Liegeois","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2025.11.023_bib144","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00442-2022","article-title":"Airway autoantibodies are determinants of asthma severity","volume":"60","author":"Salter","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib145","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202307451","article-title":"A rapid sputum-based lateral flow assay for airway eosinophilia using an RNA-cleaving DNAzyme selected for eosinophil peroxidase","volume":"62","author":"Ali","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.jaip.2025.11.023_bib146","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1039\/C6AN01563H","article-title":"Development of a functional point-of-need diagnostic for myeloperoxidase detection to identify neutrophilic bronchitis","volume":"141","author":"Wolfe","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.jaip.2025.11.023_bib147","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00303-2019","article-title":"A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation","volume":"53","author":"Shoemark","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.11.023_bib148","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/all.13711","article-title":"Rapid quantification of sputum eosinophil peroxidase on a lateral flow test strip","volume":"74","author":"Wolfe","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib149","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMoa1513737","article-title":"Patterns of growth and decline in lung function in persistent childhood asthma","volume":"374","author":"McGeachie","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1164\/rccm.202310-1759OC","article-title":"Discovery and validation of a volatile signature of eosinophilic airway inflammation in asthma","volume":"210","author":"Peltrini","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib151","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.202312-2270OC","article-title":"Exhaled volatile organic compounds for asthma control classification in children with moderate to severe asthma: results from the SysPharmPediA Study","volume":"210","author":"Shahbazi Khamas","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib152","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/cea.12147","article-title":"Predicting steroid responsiveness in patients with asthma using exhaled breath profiling","volume":"43","author":"van der Schee","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib153","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jaci.2025.02.028","article-title":"Predicting future exacerbations in uncontrolled asthma: a discovery\/validation approach using large-scale clinical proteomics","volume":"155","author":"Jurak","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.023_bib154","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17476348.2023.2278606","article-title":"Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use","volume":"17","author":"Kermani","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2025.11.023_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108975","article-title":"Merged Affinity Network Association Clustering: joint multi-omic\/clinical clustering to identify disease endotypes","volume":"35","author":"Tyler","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaip.2025.11.023_bib157","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/all.13953","article-title":"The role of mobile health technologies in allergy care: an EAACI position paper","volume":"75","author":"Matricardi","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.023_bib158","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MCP.0000000000000963","article-title":"Home monitoring in asthma: toward digital twins","volume":"29","author":"Drummond","year":"2023","journal-title":"Curr Opin Pulm Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:54:35Z","timestamp":1773975275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825011286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2213219825011286"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.023","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Treatment in Asthma\u2014Opportunities and Challenges","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}